EMAP II (Endothelial monocyte-activating polypeptide 2) is a pro-inflammatory cytokine and participant in apoptotic cell death.It is synthesized as a precursor (pro-EMAP II), lacking a secretion signal peptide.In apoptotic cells, the ~34 kDa pro-form of EMAP II is cleaved by Caspase-7 (and Caspase-3 to a lesser extent) at aspartate 144 to its mature, ~20 kDa form.The mature form of EMAP II has been found to have many different functions.In vivo, it recruits leukocytes to the site of apoptotic cell death.In vitro it has been shown to activate endothelial cells (and the release of von Willebrand factor, E-selectin and P-selectin), neutrophils, and induces macrophage expression of TNFa and TF (tissue factor).EMAP II is also a possible biomarker for brain injury, having been found to be differentially expressed in two types: traumatic injury shows an increase and ischemic injury shows a decrease in EMAP II expression (Dave, et al, 2014).

Provided assay concentrations are suggestions only, antibody titration may be required for optimal results.

A recombinant protein fragment from the C-terminal region of human EMAP II was used as the immunogen for this antibody.

Aliquot the antibody and store frozen at -20oC or colder.Avoid repeated freeze-thaw cycles.

Endothelial monocyte-activating polypeptide 2, ARS interacting multifunctional protein 1, AIMP1 antibody